A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
Sponsor: Merck Sharp & Dohme LLC
Fargo, ND · Grand Forks, ND · +22 more sites